Moderate to Severe Skin Itching (Pruritus) in Large Duct Primary Sclerosing Cholangitis
In patients with large duct primary sclerosing cholangitis, moderate to severe pruritus is a significant symptom burden requiring structured pharmacological management. Establishing the cause — and ruling out progressive bile duct strictures — is a key step before initiating treatment.
Clinical scenario
Moderate to severe pruritus (skin itching) in the setting of large duct sclerosing cholangitis, with relevant bile duct strictures excluded as the cause of progressive pruritus.
Treatment goal
Significant improvement of moderate to severe itch complaints.
Approach (partial overview)
Pharmacological treatment is recommended as first-line therapy for this symptom in sclerosing cholangitis. The specific agent and regimen are detailed in the full evidence-based protocol.
Complete algorithm — agent selection, criteria, and sequencing — available via the link below.
References
DOI: 10.1016/j.jhep.2022.05.011
- Pharmacological treatment of moderate to severe pruritus in sclerosing cholangitis with bezafibrate or rifampicin is recommended.
- It is recommended to exclude relevant bile duct strictures in large duct sclerosing cholangitis as the cause of progressive pruritus.
- We propose bezafibrate as the first-line pharmacological treatment for moderate to severe pruritus in PSC and other forms of fibrosing cholangiopathy.
- A post hoc analysis of only people with PSC again showed significant improvement of moderate to severe itch complaints.
View source ↗